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Abstract
Background: Concurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and
neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced disease.
It has previously been shown that HSP90 inhibitors act as radiosensitizers, but these studies have not focused on
CCRT in HNSCC. Here, we evaluated the HSP90 inhibitor, AUY922, combined with CCRT.
Methods: The ability of AUY922 to sensitize to CCRT was assessed in p53 mutant head and neck cell lines by
clonogenic assay. Modulation of the CCRT induced DNA damage response (DDR) by AUY922 was characterized by
confocal image analysis of RAD51, BRCA1, 53BP1, ATM and mutant p53 signaling. The role of FANCA depletion by
AUY922 was examined using shRNA. Cell cycle checkpoint abrogation and chromosomal fragmentation was
assessed by western blot, FACS and confocal. The role of ATM was also assessed by shRNA. AUY922 in combination
with CCRT was assessed in vivo.
Results: The combination of AUY922 with cisplatin, radiation and CCRT was found to be synergistic in p53 mutant
HNSCC. AUY922 leads to significant alterations to the DDR induced by CCRT. This comprises inhibition of homologous
recombination through decreased RAD51 and pS1524 BRCA1 with a corresponding increase in 53BP1 foci, activation of
ATM and signaling into mutant p53. A shift to more error prone repair combined with a loss of checkpoint function
leads to fragmentation of chromosomal material. The degree of disruption to DDR signalling correlated to
chromosomal fragmentation and loss of clonogenicity. ATM shRNA indicated a possible rationale for the combination
of AUY922 and CCRT in cells lacking ATM function.
Conclusions: This study supports future clinical studies combining AUY922 and CCRT in p53 mutant HNSCC.
Modulation of the DDR and chromosomal fragmentation are likely to be analytical points of interest in such trials.
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Background
Concurrent cisplatin radiotherapy (CCRT) is a standard-
of-care for patients with locally advanced head and neck
squamous cell carcinoma (HNSCC). Despite improving
outcomes with CCRT, patients with locally-advanced
HNSCC have a poor prognosis. Novel tumor-selective
therapies are urgently needed, with efficacy in conjunc-
tion with existing CCRT being the most likely route to
clinical development [1, 2].
HSP90 is a molecular chaperone involved in the initial
folding and continued conformational maintenance of a
pool of client proteins. Many of these have been identi-
fied as oncoproteins or key components in repair and
cell cycle arrest following exposure to DNA damaging
agents [3–5]. HSP90 inhibitors mediate sensitization
through multifaceted effects and radiosensitize a broad
range of genetically diverse tumor types [6–12].
HSP90 inhibition has been shown to have a significant
direct impact on cell cycle and DNA repair mechanisms.
HSP90 client proteins include cell cycle regulators such
as CHK1, WEE1, CDK1 and CDK4 [13, 14], as well as
DNA repair proteins such as ATR, FANCA, RAD51 and
BRCA2 [4, 15–17]. HSP90 inhibition does not alter
Ku70, Ku80 or DNA-PK total protein levels but can re-
duce phosphorylation of DNA-PKcs. This has been
shown to be due to disruption of EGFR activity via
HER2 depletion in cells lacking HER3 [17, 18]. Together
with the observation that HSP90 co-localizes with
γH2Ax repair foci [19], these previous findings suggest
HSP90 inhibition as a promising target for radio- and
chemo-sensitization studies.
AUY922 [20] is a small molecule HSP90 inhibitor
(HSP90i) that is currently recruiting in Phase II trials for
NSCLC and gastrointestinal stromal tumours. Previous
studies reported AUY922 as a radiosensitizer and that
other HSP90 inhibitors can sensitize to cisplatin alone
[21–25]. Since meaningful clinical utility for HSP90i in
HNSCC is most likely to be in the context of CCRT, we
sought to assess the combinations of AUY922 with
CCRT in p53 mutant (p53mt) HNSCC cell lines. TCGA
data has shown 85% of HPV negative HNSCC harbour
mutations in p53. Our goal was to thoroughly profile the
impact of AUY922 on DNA damage response (DDR)
signalling due to CCRT. A greater understanding of how
AUY922 modulates the DDR is crucial to establishing




Cal27 (CRL-2095) and FaDu (HTB-43) cells were ob-
tained from ATCC. LICR-LON-HN5 were a kind gift
from Suzanne Eccles (The Institute of Cancer Research,
Sutton, London, UK). All three cell lines were HPV
negative and p53 mutant. Cells were cultured in DMEM
(Invitrogen, Paisley, UK) supplemented with 10% FCS,
2 mM L-glutamine and 1% penicillin/streptomycin in a
humidified incubator at 37 °C with 5% CO2. Cells were
tested for mycoplasma using the eMyco PCR kit from
IntroBio (Seongnam-Si, South Korea) and authenticated
by STR profiling (Bio-Synthesis Inc, Texas, US).
Drugs and irradiation
AUY922 was kindly donated by Novartis in the form of
the mesylated salt. Cisplatin was from Teva Hospitals
(Castleford, UK). In western blot, confocal and FACS
analysis 10 nM AUY922 or 10 μM cisplatin was used
unless otherwise indicted. AUY922 was added 16 h be-
fore cisplatin or irradiation. Irradiation was carried out
using an AGO 250 kV X-ray machine (AGO, Reading,
UK).
Clonogenic assay
Long-term survival in response to radiation was mea-
sured by colony formation assay. Cells were trypsinized,
diluted and counted before seeding in 6-well dishes or
10 cm dishes at appropriate seeding densities. Cells were
allowed to attach before addition of 5 nM AUY922 or
DMSO only control for 16 h. Cells were exposed to
5 μM cisplatin for 3 h with cells subject to concurrent-
cisplatin radiotherapy being irradiated immediately after
cisplatin addition. After 3 h exposure to cisplatin, both
cisplatin and AUY922 were replaced by drug-free
medium. Colonies were fixed and stained in 5% gluteral-
dehyde, 0.5% crystal violet, with colonies containing
more than 50 cells counted. Colony counting was per-
formed both manually and by automated quantification
using CellProfiler 2.0 (Broad Institute, MA, USA). Sur-
viving fraction was calculated by normalization to un-
treated controls.
Western blotting
Medium and cells were harvested in PBS-containing
1 mM Na3VO4 and 1 mM NaF. Cells were pelleted be-
fore lysis in 50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1%
NP-40, 0.5% deoxycholate and 0.1% SDS. Samples were
thawed on ice, centrifuged at 14,000 rpm for 20 min at
4 °C and supernatants quantified by BCA assay from
Pierce (Leicestershire, UK). 30 μg total protein lysate
was separated by reducing SDS-PAGE, transferred to
PVDF (GE Healthcare, Bucks, UK) and blocked with 5%
non-fat dry milk in TBS. The following primary anti-
bodies were used: rabbit anti-HSP72 from Stressgen
(Exeter, UK); rabbit anti-GAPDH, rabbit anti-ATR,
rabbit anti-phospho-ATR (S428), rabbit anti-CHK1,
rabbit anti-phospho-CHK1 (S345), rabbit anti-RAD51,
rabbit anti-ATM, rabbit anti-phospho-ATM (S1981),
rabbit anti-phospho-BRCA1 (S1524), rabbit anti-
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phospho-p53 (S15) and rabbit anti-phospho-H2Ax (S139)
were purchased from Cell Signaling (MA, USA); rabbit
anti-FANCA was purchased from Bethyl Laboratories
(TX, USA). Secondary antibodies used were sheep anti-
mouse IgG and donkey anti-rabbit IgG HRP from GE
Healthcare (Buckinghamshire, UK). Chemiluminescent
detection was carried out using immobilon western sub-
strate from Millipore (East Midlands, UK). In vivo samples
were processed using a Precellys®24 homogenizer from
Bertin Technologies (Montigny, France).
Lentiviral shRNA production and infection
Short hairpin sequences were cloned into the lentiviral
shRNA plasmid pHIVSiren [26]. The plasmid pHIVSiren
was kindly donated by Professor Greg Towers, Univer-
sity College London and was derived from a parent plas-
mid, CSGW (Prof Adrian Thrasher, University College
London). FANCA and ATM short hairpin target se-
quences were 5’-GTGGCATCTTCACGTACAA-3’ and
5’-GTGGCATCTTCACGTACAA-3’, respectively. Scram-
bled short hairpin target sequence was 5’-GTTA
TAGGCTCGCAAAAGG-3’. Short hairpin containing
pHIVSiren was co-transfected with the packaging plas-
mids psPAX2, pMD2.G into HEK293T cells using lipofec-
tamine 2000 (Life Technologies, Paisley, UK). Viral
supernatants were collected and target cells infected in
the presence of 1 μg per mL polybrene.
Flow cytometry
Cells were stained for mitosis or DNA double-stranded
breaks with rabbit anti-phospho-histone H3 S10
(DD2C8) AlexaFluor647 or anti-phospho-histone H2Ax
S139 (20E3) AlexaFluor488 (Cell Signaling, MA, USA)
using the manufacturer’s protocol. Cells were analyzed
on an LSR II from BD Biosciences (Oxford, UK).
DDR confocal image based analysis
Cells were plated in 35 mm glass-bottomed dishes
(Mattek, MA, USA). Samples were fixed in 4% PFA,
permeabilized in 0.2% Triton X-100 and treated with
DNaseI (Roche, West Sussex, UK). Cells were blocked in
1% BSA, 2% FCS in PBS before staining with rabbit anti-
phospho-H2Ax S139 (γH2Ax), rabbit anti-RAD51,
rabbit anti-53BP1, anti-phospho-BRCA1 (S1524), rabbit
anti-phospho-p53 (S15) or mouse anti-phospho-ATM
(S1981) (Cell Signaling, MA, USA) with goat anti-rabbit
Alexafluor488 or goat anti-mouse Alexfluor546 as sec-
ondary antibodies (Invitrogen, Paisley, UK). Nuclei were
counterstained with DAPI. Samples were imaged using a
Zeiss LSM710 inverted confocal microscope (Zeiss, Jena,
Germany). Automated quantification of foci in 100-300
nuclei per experiment was carried out using CellProfiler
2.0 (Broad Institute, MA, USA). Formalin-fixed paraffin
embedded (FFPE) in vivo blocks were sectioned and
antigen retrieved for RAD51 (pH9 Tris-EDTA) or 53BP1
(pH6 citrate buffer). Antigen retrieved slides were
blocked, stained, imaged and quantified as outlined for
in vitro samples above.
In vivo human xenograft model
Female 5-6 week-old athymic BALBc nude mice
(Charles River, UK) were used with all experiments,
complying with NCRI guidelines. 2x106 FaDu cells were
injected subcutaneously. Developing tumors were dis-
tributed into groups containing a minimum of n = 8 per
group, with matching average tumor volumes. AUY922
40 mg/kg in 5% dextrose was administered in three
doses by i.p. injection on days one, three and five. Frac-
tionated radiation treatment of the tumor consisted of a
total dose of 6 Gy in 2 Gy fractions on day two, four and
six. Cisplatin was administered as a single dose of 5 mg/
kg on day four immediately before irradiation. Tumor
volume was calculated as volume = (width × length ×
depth)/2 and was plotted as mean tumor volume for
each group.
Statistical analysis
Statistical analysis was carried out using Graphpad prism
(version 6.0f ). Unpaired two-tailed student t-test was
utilized for parametric analysis. Synergy was determined
by Bliss independence analysis using the equation Eexp =
Ex + Ey – (ExEy) [27]. Eexp is the expected effect if two
treatments are additive with Ex and Ey corresponding to
the effect of each treatment individually. ΔE = Eobserved -
Eexp. Synergy is represented by ΔE and 95% confidence
intervals (CI) from observed data all above zero; addition
to values above and below zero; antagonism where all
values are below zero.
Results
AUY922 sensitizes p53mt HNSCC to cisplatin, radiation
and concurrent-cisplatin radiotherapy (CCRT)
The ability of AUY922 to sensitize to cisplatin, radiation
and CCRT was assessed in a panel of cell lines by clono-
genic assay using the scheduling outlined (Fig. 1a). We
focused our studies on p53mt since p53 pathway abnor-
malities exist in 85% of HPV-negative HNSCC (TCGA).
Clonogenic data are presented as surviving fractions,
normalised to drug free control wells (Fig. 1b). Qualita-
tive images of colonies for each cell line and condition
are also shown with numbers indicating the number of
cells plated in each well shown (Fig. 1c). Bliss independ-
ence analysis (Fig. 1d) indicated synergy for the combin-
ation of AUY922 and cisplatin, except HN5 in which the
interaction was additive. Synergy for the combination of
AUY922 with both radiation and CCRT was observed in
all cell lines tested. Values for synergy between 0 and 0.2
are in keeping with those observed in recent
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Fig. 1 Clonogenic survival and Bliss analysis for concurrent cisplatin radiotherapy (CCRT) and AUY922. Clonogenic survival assay showing cisplatin,
radiation, or CCRT sensitizing effect of HSP90i by AUY922 on p53 mutant head and neck cell lines CAL27, FaDu and HN5. a Clonogenic drug
scheduling. 5 nM AUY922 was added 16 h before addition of 5 μM cisplatin and/or immediate irradiation. Cisplatin and AUY922 were replaced
with fresh media 3 h post-radiation. b Surviving fractions were calculated by normalization of treated wells to the plating efficiency of untreated
controls. Values ± SEM of at least 3 independent experiments. Statistical analysis by 2-tailed t-test; *p < 0.05, **p < 0.01, ***p < 0.001. c Representative
images of colonies for each cell line and each condition. Numbers indicate number of cells plated per well shown. d Analysis of synergy for the
addition of AUY922 to cisplatin, radiation or CCRT as indicated by the Bliss Independence Model plotted as ΔE values ± 95% confidence intervals.
ΔE = Observed reduction in clonogenicity – Expected reduction in clonogenicity, with survival expressed as a fraction of 1. Values with confidence
intervals falling above zero represent synergy, negative values antagonism
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radiosensitization studies for CHK1 and ATR inhibition
[28, 29]. FaDu cells were substantially more sensitive to
AUY922 and cisplatin monotherapies as well as AUY922
and cisplatin or CCRT combinations. HN5 cells were
more resistant to monotherapies and were one to two
orders of magnitude more resistant to the combination
of AUY922 and CCRT compared to other cell lines.
Inhibition of HR via RAD51 and BRCA1 corresponds to
increased 53BP1 foci and signalling into mutant p53
We investigated the impact of AUY922 on CCRT-
induced RAD51 focus formation. CCRT induced an in-
crease in early RAD51 focus formation which was sig-
nificantly reduced by AUY922 (Fig. 2a, b). Western blots







Fig. 2 AUY922 reduces HR in response to CCRT but increases 53BP1 focal formation and mutant p53 signaling. a Representative images of
RAD51 foci in the HNSCC cell lines CAL27, FaDu and HN5. Nuclear localization indicated by DAPI staining. AUY922 refers to 10 nM added 16 h
pre-DNA damage. 2 Gy radiation plus 10 μM cisplatin for brevity is referred to as concurrent-cisplatin radiotherapy (CCRT). b Quantitation of the
average RAD51 foci per nucleus at 4 h and for CCRT and CCRT + AUY922 conditions at 24 h also. Values shown are means ± SEM of a minimum
of three independent experiments. c Western blot analysis of pS1524 BRCA1 and pS15 p53 signaling post irradiation or cisplatin treatment. d, e, f
Automated image based quantification of average nuclear pS1524 BRCA1 intensity, average pS15 p53mt nuclear intensity, and average 53BP1 foci
per nucleus with treatment schedule as outlined in panel b. Representative nuclear staining for each cell line and condition are shown. Values
shown are means ± SEM from a minimum quantification of 12 fields of view across two independent experiments, except for pS1524 BRCA1 in
CAL27 cells which represent 8-10 fields of view from a single experiment. Statistical analysis by 2-tailed t-test; *p < 0.05, **p < 0.01, ***p < 0.001
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alone revealed similar levels of S1524 BRCA1 in all cell
lines, but diverse phosphorylation of mutant p53 S15.
FaDu cells were constitutively high for pS15 p53 with
levels in HN5 cells rapidly decreasing after an early radi-
ation induced spike (Fig. 2c).
To more conclusively investigate this difference we
looked at nuclear staining of pS1524 BRCA1, pS15 p53
and 53BP1 focus formation. Nuclear intensity of pS1524
BRCA1 signalling increased due to CCRT and was statisti-
cally lower due to AUY922 (Fig. 2d). Nuclear intensity of
CCRT induced pS15 p53 increased in all cell lines due to
the addition of AUY922 (Fig. 2e). CCRT induced 53BP1
foci increased in all cell lines due to the addition of
AUY922 (Fig. 2f). Overall it was observed that FaDu cells
exhibited the highest basal levels of RAD51, 53BP1 and
pS15 p53 with the largest number of CCRT induced
RAD51 and 53BP1 foci. HN5 cell displayed the lowest
basal DDR signalling pattern and low levels of RAD51 foci
persisting at 24 h as well as low levels of pS15 mutant
p53. Cal27s fell in between, with this pattern correlating
to the results observed in clonogenic assays (Fig. 1b).
FANCA and RAD51 depletion by AUY922 perturbs normal
RAD51 focus formation and increases ATM focus
formation in response to CCRT
Previously reported as a HSP90 client protein, we inves-
tigated how FANCA and RAD51 depletion may impact
ATM signalling (measured by autophosphorylation on
S1981). AUY922 depleted both RAD51 and FANCA to
similar levels in CAL27, FaDu and HN5 cells with ca-
nonical drug-on-target induction of HSP72 (Fig. 3a).
Stable knockdown in CAL27 cells of FANCA and ATM
by lentiviral shRNA is shown by western blot (Fig. 3b).
As expected, FANCA knockdown increased sensitivity
to cisplatin and CCRT with no statistically significant
difference between control and scrambled shRNA condi-
tions (Fig. 3c). FANCA knockdown significantly in-
creased basal RAD51 and pS1981 ATM focus formation
in response to CCRT (Fig. 3d, e). CCRT-induced pS1981
ATM foci were further increased by the addition of
AUY922 in all cell lines (Fig. 3e, f ) coinciding with a re-
duction in RAD51 foci (Fig. 2b, Fig. 3d).
We then generated ATM knockdown cells to investigate
the role of ATM in compensating for loss of RAD51 and
FANCA due to AUY922. Knockdown of ATM in CAL27
cells resulted in increased sensitivity to cisplatin, radiation
and CCRT (Fig. 3g). AUY922 was able to further sensitize
to cisplatin, radiation or CCRT. Overall survival was pro-
foundly decreased in all combinations vs scrambled.
AUY922 abrogates ATR-CHK1 signaling and induces
chromosomal fragmentation
Following on from evidence of increased ATM foci in-
duced by AUY922, we looked at ATR-CHK1 signaling.
In all cell lines, moderate decreases in phospho-ATR,
total-ATR and total-CHK1 combined to give a substan-
tial reduction in phospho-CHK1 signaling (Fig. 4b). In
studying the impact of this inhibition on mitotic entry
by phospho-histone H3 staining (Fig. 4c), AUY922 was
found to induce a profound increase in the mitotic
population. This was much less pronounced in CAL27
cells, while HN5 cells exhibited an increase in the mi-
totic population from 2.9 to 8.1% due to AUY922 treat-
ment (data not shown).
Co-staining FACS analysis of both the mitotic marker
phospho-histone H3 and the double-stranded break
marker γH2Ax revealed that this AUY922-induced mi-
totic population became highly γH2Ax positive immedi-
ately after CCRT (Fig. 4d). Confocal microscopy (Fig. 4e)
further confirmed the presence of high levels of γH2Ax
foci in nuclei displaying a mitotic morphology post-
CCRT, as well as chromosome fragments or missegrega-
tion. We quantified the presence of micronuclei at 24 h
post CCRT (Fig. 4f ). AUY922 alone increased micronu-
clei compared to basal and significantly increased micro-
nuclei when combined with CCRT vs CCRT alone in all
cell lines.
FaDu cells showed high levels of chromosomal frag-
mentation both basally and in response to AUY922 plus
CCRT. HN5 cells showed low basal levels and the lowest
number of micronuclei in response to CCRT plus
AUY922. This pattern of micronuclei formation closely
aligned to that observed for RAD51, 53BP1 repair foci
formation and signalling into mutant p53 (Fig. 2b, e, f ).
This DNA repair foci pattern and micronuclei gener-
ation correlated to the differences in sensitivity observed
in clonogenic assays (Fig. 1b) with FaDus being the most
sensitive and HN5s the most resistant.
AUY922 enhances growth delay of CCRT treated FaDu
HNSCC xenograft tumors
DNA damage signaling basally and in response to radi-
ation was assessed in FaDus in vivo (Fig. 5a). Cisplatin
treatment of FaDu xenografts was confirmed to increase
DNA damage signaling 24 h after 5 mg/kg cisplatin in-
jection (Fig. 5b, c). Depletion of HSP90 client proteins
by AUY922 in FaDu xenografts was assessed at both
40 mg/kg and 80 mg/kg with three IP injections on days
1, 3 and 5. Tumor lysates were collected 24 h after final
injection. HER2 as a known and highly sensitive HSP90
client protein was also assessed. Reductions in RAD51
and HER2 were observed at 40 mg/kg with increased
S15 phospho-p53 signaling also detected (Fig. 5b, c).
The lowest dose of 40 mg/kg AUY922 was selected to
look for sensitization effects in tumor volume experi-
ments (Fig. 5d). Mice were treated when tumors reached
5-7 mm in width with groups composed of mice with
equal average tumor volume. AUY922 40 mg/kg was
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administered by IP injection on days 1, 3 and 5. Radi-
ation was delivered in 3 × 2 Gy fractions on days 2, 4
and 6 with 5 mg/kg cisplatin administered by IP injec-
tion before irradiation on day 4. CCRT combined with
AUY922 was tolerable with average weight loss of <10%
(data not shown). The addition of AUY922 successfully
delayed time to reach 800 mm3 from 27 days for CCRT
only to 34 days from CCRT plus AUY922.
To assess DDR signalling at the level of repair foci for-
mation in vivo, staining for RAD51 and 53BP1 was car-
ried out on sections from FFPE tumour blocks which
were all fixed 16 h after the final radiation fraction. Cis-
platin and radiation combined to increase RAD51 foci in
vivo, with AUY922 at the 40 mg/kg dose used in therapy
experiments able to reduce RAD51 focus formation
(Fig 5e). 53BP1 focus formation as a result of radiation
decreased due to the addition of cisplatin. AUY922
addition to CCRT in increased the number of 53BP1 foci
detected. These findings are in line with those shown in
vitro (Fig. 2b, f ).
Discussion
The standard-of-care for locally advanced HNSCC is
CCRT, yet almost 50% of patients do not survive past
5 years [30]. The anti-EGFR-targeting monoclonal anti-
body cetuximab is the only targeted therapy approved
for HNSCC treatment. However, the RTOG 0522 phase






Fig. 3 AUY922 disruption of FANCA leads to increased dependency on ATM in response to CCRT. a Western blot analysis of RAD51 and FANCA
depletion by AUY922 in the p53mt HNSCC cell lines CAL27, FaDu and HN5. b Confirmation of FANCA and ATM knockdown using lentiviral
shRNA by western blot in the p53 mutant HNSCC cell line CAL27 vs scrambled shRNA. c Clonogenic survival assay showing cisplatin; radiation; or
CCRT toxicity to CAL27 cells expressing scrambled (SCR) or FANCA shRNA vs control cells with no lentiviral infection. d, e Quantification of RAD51
or S1981 phospho-ATM foci by confocal microscopy in SCRsh or ATMsh CAL27 cells. CCRT and AUY922 doses as outlined in Fig. 2. f S1981
phospho-ATM foci in FaDu and HN5 cells in response to CCRT and AUY922. g Clonogenic survival assay showing cisplatin, radiation, or CCRT
sensitizing effect of HSP90i by AUY922 in scrambled of ATM shRNA expressing CAL27 cells. All values mean ± SEM of at least 3 independent
experiments. Statistical analysis by 2-tailed t-test; *p < 0.05, **p < 0.01, ***p < 0.001






Fig. 4 AUY922 abrogates ATR-CHK1 signaling allowing increased chromosomal fragmentation in response to CCRT. a Scheduling showing 0 h
time point post 16 h AUY922 addition but pre-RT, cisplatin or combined CCRT addition and subsequent time point analysis post as used in panels
b-f. b AUY922 disruption of ATR-CHK1 signaling in response to CCRT alongside depletion of total RAD51. c Mitotic accumulation as measured by
FACS analysis of phospho-histone H3 positive cells. d Co-staining for phospho-histone H3 and γH2Ax was analyzed by FACS. Population plotted
is the percentage of the total cell number positive for both high γH2Ax levels and the mitotic marker phospho-histone H3. e γH2Ax staining in
mitotic cells was confirmed in HNSCC cell lines by confocal microscopy, DAPI as nuclear stain. Nuclei with mitotic morphology indicated by
arrows. f Micronuclei quantification of DAPI stained confocal images at 24 h in response to CCRT and AUY922. Values are mean ± SEM of at least
three independent experiments. Statistical analysis by 2-tailed t-test; *p < 0.05, **p < 0.01, ***p < 0.001
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cetuximab to cisplatin-based CCRT [31]. Cetuximab il-
lustrates that success in clinical trials is likely to be mea-
sured by the capability to improve survival as an
addition to CCRT rather than with radiation alone.
Our goal in this study was to iterate on the already
established ability of HSP90 inhibition to radiosensitize.
We set out to determine if HSP90 inhibition in combin-
ation with CCRT was likely to offer a significant step-
wise improvement or if the addition of cisplatin had the
potential to interfere with radiation sensitization by
AUY922. The addition of AUY922 to cisplatin, radiation
and CCRT combinations was shown to be synergistic
across a panel of p53mt. AUY922 and was capable of en-
hancing the efficacy of CCRT in vivo.
Sensitization to CCRT by HSP90i has previously been
published in both NSCLC [21] and bladder cancer [25].
Wang et al. examined the ability of HSP90i by ganete-






Fig. 5 AUY922 delays tumor growth in conjunction with CCRT. a FaDu cells were implanted subcutaneously in BALB/c nude mice. After reaching
5-7 mm, tumors were treated with 2 Gy radiation. Tumors harvested at the times post radiation as indicated and probed for DNA damage signal-
ing by western blot. b FaDu cells implanted as in A before treatment with cisplatin 5 mg/kg or three doses of AUY922 40 mg/kg on alternate
days. Tumors treated with AUY922 were collected 16 h post final injection, cisplatin 24 h post injection. Western blot analysis performed for DNA
damage signaling in response to cisplatin or reduction in HSP90 client proteins by AUY922. c Densitometry of changes due to HSP90 inhibition
and response to cisplatin as shown in panel b, expressed as arbitrary scanning units adjusted for changes in GAPDH levels.
d FaDu cells implanted as in A. Tumors were distributed into the following treatment groups with matching average tumor volumes; control;
Cisplatin 5 mg/kg; AUY922 40 mg/kg × 3; cisplatin 5 mg/kg plus AUY922 40 mg/kg × 3; cisplatin 5 mg/kg plus three fractions of 2Gy; cisplatin
5 mg/kg plus three fractions of 2 Gy plus AUY922 40 mg/kg× 3. Exact scheduling as outlined in methods. Tumor volume expressed as percentage
increase over basal volume at start of treatment. e, f FFPE blocks were sectioned and stained for RAD51 and 53BP1 foci. Automated quantification
shown represents a minimum of 36 randomly distributed fields of view for RAD51 across 2 tumor blocks, 16-24 fields of view across for 53BP1 foci.
Values ± SEM, statistical analysis by 2-tailed t-test; *p < 0.05, **p < 0.01, ***p < 0.001
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KRAS wt p53 mt/null cell lines [21]. Ganetespib radio-
sensitized all cell lines but they showed HSP90i pro-
duced variable results both in vitro and in vivo to
carboplatin-paclitaxel and concomitant carboplatin-
paclitaxel and radiation. The use of paclitaxel-
carboplatin rather than carboplatin alone complicates in-
terpretation of these results relative to our study. We see
broad sensitization to CCRT while they see cases of an-
tagonism by HSP90i. This could be cell line specific or
related to paclitaxel. Yoshida et al. assessed cisplatin and
radiation in bladder cancer cell lines showing
sensitization by 17-DMAG to radiation and CCRT [25].
While a number of studies have looking at HSP90i
sensitization to radiation or cisplatin individually in head
and neck [12, 24, 32], none extensively address the abil-
ity of HSP90i to sensitize p53mt HNSCC to concurrent-
cisplatin radiotherapy.
We concentrated on investigating the ability of
AUY922 to disrupt HR induced by CCRT and other
DDR signalling pathways by extensive confocal image
based analysis. RAD51, BRCA1 and BRCA2 have previ-
ously been identified as HSP90 client proteins, with de-
pletion of RAD51 and RAD52 occurring upon loss or
inhibition of HSP90 isoforms in budding yeast [17, 23,
33]. Previous mechanistic studies on HSP90i have not
focused extensively on DDR signalling. In the HSP90i
and platinum-radiotherapy combinations mentioned
above, 53BP1 foci alone were analysed but only for gane-
tespib and radiation [21]. For HSP90i and CCRT in blad-
der cancer, mechanistic studies focused on HER2 and
AKT signalling with no investigation of the impact of
HSP90i on DDR signalling [25]. Likewise studies into
sensitization to radiation or cisplatin alone often focused
on cell cycle, growth and apoptotic signalling pathways
[22, 24, 32, 34–36]. Choi et al. identified HSP90i by bio-
informatics as a means to convert HR proficient to HR
deficient tumours [23] but DDR analysis was restricted
to γH2Ax and RAD51 foci formation as has been the
case in other studies [17, 22, 35].
In this study we comprehensively profiled HSP90i
modulation of the DDR to CCRT. Reduction in HR by
HSP90i occurs due to decreased RAD51 focus formation
and nuclear pS1524 BRCA1. This corresponds to
HSP90i induced increases in 53BP1 foci. This may be in
part a separate inhibitory event on the resolution of
53BP1 repair sites or a switch from HR to NHEJ. 53BP1
has been identified to antagonise DSB end resection pro-
moting NHEJ over HR. It has been proposed that 53BP1
is displaced in S-phase in a BRCA1 dependent manner.
The role of BRCA1 in promoting HR over NHEJ
through 53BP1 has been recently reviewed [37, 38]. This
suggests HSP90i via a reduction in nuclear BRCA1 sig-
nalling may also shift HR to more error prone NHEJ re-
pair rather than a delay in existing 53BP1 foci resolution
alone. Modulation of DDR at the repair foci level in vivo
has also been demonstrated for the first time in FFPE
blocks. This may be a beneficial for analysis of future
clinical trials where FFPE biopsies are more routinely
used for analysis.
HSP90i increased CCRT induced nuclear pS15 p53mt
levels. The role this increased p53mt signalling may play
is not known. The early HSP90 inhibitor 17-AAG has
been shown to stabilise wild type p53 in head and neck
cell lines through a reduction in MDMX increasing
apoptosis in response to cisplatin [24]. Parallel studies
were not performed on mutant p53.
In exploring the role the HR component FANCA may
play in HSP90 chemosensitization, we discovered a pro-
found increase in ATM foci in response to AUY922.
FANCA is part of the Fanconi Anemia core complex
that ubiquitinates FANCD2 at interstrand crosslink sites,
leading to crosslink unhooking, lesion bypass and down-
stream completion of repair by RAD51-mediated HR
[39]. FANCA depletion alone by shRNA revealed an in-
crease in RAD51 alongside increased ATM focus forma-
tion. It is not known if FANCA loss results in a
numerical increase in the incidence of damage requiring
RAD51 and ATM focus formation or simply prevents
the timely resolution of existing cisplatin adducts leading
to accumulation. The exact cause of this increased ATM
signal due to AUY922 is hard to pinpoint. ATM is
autophosphorylated on Ser1981 [40]. FANCA mutation
and ATR loss have both been shown to increase phos-
phorylation of S1981 ATM and S15 p53 [41, 42] with
ATM known to phosphorylate S15 of p53 in response to
DNA damage [43]. This suggests decreased levels of
ATR and FANCA by HSP90i lead to compensatory sig-
nalling via ATM and p53 in response to CCRT. An illus-
tration of the hypothesised changes in CCRT induced
DDR signalling triggered by HSP90i and downstream
consequences is summarised in Fig. 6.
Decreased RAD51, FANCA and ATR function by
HSP90 inhibition may lead to increased dependence on
ATM for repair. Cells subject to ATM knockdown by
shRNA were substantially more sensitive to cisplatin, RT
and CCRT alone and in combination with HSP90i. Loss
of ATM has been shown to occur in head and neck due
to loss of the distal region of chromosome 11q [44].
Much discussion has occurred around the potential to
target ATM loss as a synthetic lethal strategy [45]. ATR
inhibition alone is being investigated as a radiosensitizer
with some studies showing ATR inhibition leading to in-
creased dependency on ATM [46, 47].
The ultimate consequence of a shift to more error
prone repair and loss of S-phase and G2/M checkpoint
fidelity was missegregation of chromosomal material and
micronucleus formation. We observed that the most
sensitive cell line in clonogenic assays (FaDu) displayed
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the highest levels of DDR signalling due to CCRT and
the highest levels of chromosomal fragmentation with
the addition of HSP90i. The least sensitive cell line in
clonogenic assays (HN5) displayed the lowest levels of
both DDR signalling and chromosomal fragmentation.
Micronuclei deficient in nuclear import, prone to rup-
turing and incomplete replication [48, 49] are putatively
the major toxic event induced by AUY922 inhibition in
combination with CCRT.
Conclusions
In summary, this study demonstrated inhibition of
HSP90 by AUY922 had a synergistic interaction with
CCRT in a panel of p53 mutant cell lines. HSP90i leads
to significant alterations to the DDR induced by CCRT.
This comprises inhibition of HR, a shift to more error
prone repair and loss of checkpoint function leading to
fragmentation of chromosomal material. Additionally,
these results indicate there may be a rationale for the
combination of AUY922 and CCRT in cells lacking
ATM function. In conclusion, these data show that
HSP90 inhibition can improve upon CCRT standard-of-
care and support further preclinical and clinical studies
in HNSCC.
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